Skip to content
TrialScanner

NCT03238027

A Phase 1 Study to Investigate Axatilimab Alone or in Combination With Durvalumab in Patients With Solid Tumors

Phase 1CompletedSNDXLead

Registry record

Lead sponsor
Syndax Pharmaceuticals
Conditions
Solid Tumor; Metastatic Tumor; Locally Advanced Malignant Neoplasm; Unresectable Malignant Neoplasm
Primary completion
Nov 20, 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03238027 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03238027: A Phase 1 Study to Investigat... | TrialScanner